A5006441433- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Renal and related cancers
- Multiple and Secondary Primary Cancers
- Prostate Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Bladder and Urothelial Cancer Treatments
- PARP inhibition in cancer therapy
- Infectious Diseases and Mycology
- Cancer-related Molecular Pathways
- Urologic and reproductive health conditions
- Antifungal resistance and susceptibility
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Reproductive Biology and Fertility
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- Breast Cancer Treatment Studies
- Hormonal and reproductive studies
- Ovarian function and disorders
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
University of Calgary
2024-2025
Baker Hughes (Canada)
2024
Instituto Alexander Fleming
2022-2024
Hospital Italiano de Buenos Aires
2018
494 Background: Immuno-oncology (IO)-based combination therapy with or without anti-vascular endothelial growth factor (VE) has become a standard of care for mnccRCC. However, real-world evidence on the effectiveness contemporary therapies over traditional targeted against mnccRCC is limited. Methods: Using IMDC, patients were classified into five subgroups based 1L therapies: IOIO, IOVE, CABO, SUN/PAZ, and mammalian target rapamycin (mTOR). Baseline patient characteristics, clinician...
In recent years, unprecedented benefits have been observed with the development of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for treatment hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. However, there is scarce evidence their value in specific populations, such as patients carrying germline pathogenic variants DNA repair-related genes.We retrospectively studied efficacy CDK 4/6 plus endocrine therapy advanced Three cohorts were...
4514 Background: The role of immunotherapy combinations in mRCC with IMDC favorable risk is controversial. A very subgroup patients (primary diagnosis to systemic therapy ≥3yr, Karnofsky Performance Status 90 or 100% and absence brain, liver, bone metastasis) has been described by Schmidt A. et al., which require characterization the immuno-oncology combination era. Methods: Using IMDC, we selected who started during 2016-2023 examined group subset patients. First line was divided into 3...
477 Background: Multiple phase 3 trials have established either dual immunotherapy with ipilimumab and nivolumab (IPI-NIVO) or a VEGFR inhibitor (IO-VE) as standard-of-care first-line therapy for metastatic clear cell renal carcinoma (mRCC). We focused this analysis on patients IMDC intermediate poor risk where IPI-NIVO IO-VE would be standard. Methods: Using the database, we performed retrospective of disease (1 more factors) who received an approved combination (avelumab-axitinib,...
479 Background: Cabozantinib is approved as a subsequent therapy for patients with metastatic renal cell carcinoma (mRCC) based on the METEOR trial. However, only 5% of in this trial received prior immunotherapy. Methods: We identified mRCC from IMDC who were treated cabozantinib second-line (2L) setting 2010 to 2023. These stratified by risk groups and first-line (1L) treatment. analyzed overall response rate (ORR), time next treatment (TTNT), duration (TD), survival (OS) performed...
505 Background: The IMDC model has been effectively used to predict patients’ (pts) outcomes with mRCC, significantly guiding treatment decisions in the era of immune checkpoint inhibitors (ICIs) that have improved survival. In this study, we aim characterize clinical between patients classified as low (L, score 0) vs. low-intermediate (L/I, 1) categories. Methods: Data pts mRCC receiving first-line (1L) ICI-based therapies scores 0 or 1 was collected from IMDC. Pts were further subdivided...
509 Background: Comorbidities pose a challenge in the treatment of patients with cancer and present barrier to inclusion clinical trials. While effect comorbidities on efficacy immunotherapy (IO) has been studied various malignancies, it remains unclear metastatic renal cell carcinoma (mRCC) treated IO-based combinations. Methods: Data from mRCC receiving combinations (IO+IO or IO+anti-vascular endothelial growth factor (VEGF)) as first-line were collected Dana-Farber Cancer Institute Tom...
4538 Background: Lenvatinib is a tyrosine kinase inhibitor (TKI) that targets both vascular endothelial growth factor (VEGF) receptor and fibroblast receptor. It has demonstrated efficacy in the upfront refractory disease settings. However, there lack of data surrounding TKIs post-lenvatinib exposure. In this study, we investigate activity therapies pts with aRCC. Methods: We conducted retrospective analysis utilizing International Metastatic Database Consortium (IMDC). Pts having received...
1056 Background: HER2-low expression, defined as HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization assay (FISH), accounts for 50% breast cancers. There is limited and conflicting evidence regarding the efficacy cyclin-dependent kinase (CDK) 4 6 inhibitors patients ER+ tumors. This study aimed to investigate prognostic value expression ER+/HER2-negative advanced cancer treated CDK 4/6 inhibitors. Methods: We retrospectively selected consecutive plus...
PURPOSE This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC). PATIENTS AND METHODS is a retrospective, multicenter cohort mPC and reports on testing. Patients were included from 12 academic centers in five countries. RESULTS A total 349 PC this study. Most (209, 59.9%) de novo metastatic. Genomic analysis was performed 233 (66.6%) the castration-resistant (mCRPC) setting, only 115 (32.8%) had tumor evaluation hormone sensitive scenario. The...
4529 Background: Adjuvant pembrolizumab significantly improved overall survival (OS) and is FDA-approved for adjuvant RCC treatment. However, there a paucity of data on sequential treatment following recurrence after or other immune-oncology (IO)-based therapies (PD-1 PD-L1 inhibitors) administered in the setting. Methods: This study included consecutive patients (pts) from 27 international centers who received IO-based systemic therapies. Safety efficacy subsequent therapy regimens that...
Abstract Background In Phase 3 trials, the assessment for primary endpoint of overall survival (OS) necessitates extended follow-up periods, a larger pool events, and higher associated costs. Hence, we sought to determine whether shorter intermediate (IEs) such as Objective Response (OR), Time Treatment Failure (TTF) Next Therapy (TTNT) are with OS in patients receiving immune checkpoint (ICI)-based therapy. Methods We included all International mRCC Database Consortium (IMDC) who received...
Abstract Background Lenvatinib is a tyrosine kinase inhibitor (TKI) that targets both vascular endothelial growth factor (VEGF) receptor and fibroblast receptor. It has demonstrated efficacy in the upfront refractory disease settings. However, there lack of data surrounding TKIs post-lenvatinib exposure. In this study, we investigate activity therapies patients with aRCC. Methods We conducted retrospective analysis utilizing International Metastatic Database Consortium (IMDC). Patients...
Previous studies with bipolar androgen therapy (BAT) have shown clinical activity in metastatic Castration Resistant Prostate Cancer (mCRPC) as well the potential to re-sensitise prostate cancer cells prior receptor-targeted agents. None of these had tested BAT after chemotherapy. In this study, we gathered real-world evidence from three centres Argentina where is being used castration-resistant (CRPC), not only chemotherapy but also several lines treatment.This retro-prospective...

 Introducción: La terapia bipolar androgénica (BAT) es una estrategia para pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm). Estudios previos demostraron actividad clínica, así como también el potencial efecto re- sensibilizar las células un agente hormonal utilizado previamente. Ninguno evaluó BAT luego quimioterapia. Materiales y métodos: Estudio cohorte multicéntrico retrospectivo CPRCm que recibieron quimioterapia en tres centros...

 El PET/TC-PSMA es una técnica de imagen no invasiva que demostró ser más sensible y específica comparado con el PET-Colina, sobre todo valores PSA <1 ng/ml. Últimamente su utilización ha ganado terreno tiene indicaciones precisas en enfermedad localizada alto riesgo recaída bioquímica.
 Los objetivos del presente estudio fueron identificar las PET/TC PSMA evaluar impacto resultado la indicación terapia dirigida a metástasis.
 Se trata un descriptivo,...

 Los tumores de Sertoli-Leydig (TSL) del ovario son una afección poco frecuente, clasificado dentro los cordones sexuales y estromales. Al ser infrecuentes, heterogéneos desde el punto vista patológico presentarse en pacientes jóvenes edad reproductiva, un verdadero desafío diagnostico terapéutico.
 Se presentan 3 casos clínicos, primero paciente 43 años con paridad cumplida gran tumor localizado ovario, caso 2 es 26 avanzado 33 recaída luego tratamiento primario. tres...